Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | UBE2N | P61088 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170909 | 0.82 | KDM4E (0.49) | CA1CA2KDM4EUBE2NRAPGEF4 | |
| SCHEMBL22689650 | 0.81 | FBP1 (0.44) | CA1CA2KDM4EUBE2NRAPGEF4 | |
| SCHEMBL22689649 | 0.81 | FBP1 (0.44) | CA1CA2KDM4EUBE2NRAPGEF4 | |
| SCHEMBL30781523 | 0.75 | CA1 (0.43) | CA1CA2KDM4EUBE2NRAPGEF4 | |
| SCHEMBL2184458 | 0.75 | CA1 (0.43) | CA1CA2KDM4EUBE2NL3MBTL1 | |
| SCHEMBL3464148 | 0.73 | ALDH1A1 (0.40) | CA1CA2KDM4EUBE2NRAPGEF4 | |
| SCHEMBL28904396 | 0.73 | CA1 (0.49) | CA1CA2KDM4EUBE2NRAPGEF4 | |
| SCHEMBL28538858 | 0.73 | CA1 (0.49) | CA1CA2KDM4EUBE2NRAPGEF4 | |
| SCHEMBL18951969 | 0.73 | CA1 (0.49) | CA1CA2KDM4EUBE2NRAPGEF4 | |
| SCHEMBL30625972 | 0.72 | CA1 (0.43) | CA1CA2KDM4EUBE2NRAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113544131-B | Pyrrolo-heterocyclic derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20220204512-A1 | SUBSTITUTED FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| US-20220185818-A1 | PYRROLOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2022-06-16 | — | — | US | disclosed |
| EP-3978498-A1 | SUBSTITUTED FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINES | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185818-A1 | PYRROLOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE | MAPKAP1, WEE1, WEE2 | CA1 4654/4885CA2 4608/4885KDM4E 3586/4885 |
| US-20220204512-A1 | SUBSTITUTED FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINES | WEE1, MAPK8, WEE2 | CA1 4814/4885CA2 4749/4885KDM4E 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.